Cited 0 times in
Prognostic value of prostate volume in non-muscle invasive bladder cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김종찬 | - |
dc.contributor.author | 박지수 | - |
dc.contributor.author | 장원식 | - |
dc.contributor.author | 최영득 | - |
dc.contributor.author | 함원식 | - |
dc.date.accessioned | 2021-11-19T01:41:20Z | - |
dc.date.available | 2021-11-19T01:41:20Z | - |
dc.date.issued | 2021-09 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/185981 | - |
dc.description.abstract | There is evidence that a history of benign prostatic hyperplasia increases the incidence of bladder cancer, and treatment with 5-alpha reductase inhibitor or androgen deprivation therapy reduces recurrence of non-muscle invasive bladder cancer. We aimed to evaluate whether prostate volume affects its prognosis. We reviewed medical records of men who underwent transurethral resection of bladder tumor due to non-muscle invasive bladder cancer from January 2012 to December 2017. Patients were divided into two groups based on prostate volume measured by computed tomography (group 1: 264 patients with ≤ 30 mL, group 2: 124 patients with > 30 mL). Propensity score matching analysis was used for adjust selection bias, and then assessed recurrence-free survival and progression-free survival. With a median follow up duration of 52 months, group 1 showed higher 5-year recurrence-free and progression-free survival (69.3% vs 47.0%, p = 0.001; 96.7% vs 87.7%, p = 0.002). Further, cox-regression analysis showed that tumor size (HR = 1.292 p < 0.001), multifocal tumor (HR = 1.993, p < 0.001), adjuvant intravesical therapy (chemotherapy: HR = 0.580, p = 0.037 and bacillus Calmette-Guérin: HR = 0.542, p = 0.004) and prostate volume (HR = 2.326, p < 0.001) were significant predictors of recurrence-free survival. Prostate volume (HR = 2.886, p = 0.014) was also associated with PFS with age (HR = 1.043, p = 0.044) and tumor grade (HR = 3.822, p = 0.013). We conclude higher prostate volume is associated with worse recurrence and progression-free survival in non-muscle invasive bladder cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Prognostic value of prostate volume in non-muscle invasive bladder cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Urology (비뇨의학교실) | - |
dc.contributor.googleauthor | Won Sik Ham | - |
dc.contributor.googleauthor | Jee Soo Park | - |
dc.contributor.googleauthor | Won Sik Jang | - |
dc.contributor.googleauthor | Young Deuk Choi | - |
dc.contributor.googleauthor | Jongchan Kim | - |
dc.identifier.doi | 10.1038/s41598-021-98045-1 | - |
dc.contributor.localId | A04541 | - |
dc.contributor.localId | A05336 | - |
dc.contributor.localId | A05268 | - |
dc.contributor.localId | A04111 | - |
dc.contributor.localId | A04337 | - |
dc.relation.journalcode | J02646 | - |
dc.identifier.eissn | 2045-2322 | - |
dc.identifier.pmid | 34552102 | - |
dc.contributor.alternativeName | Kim, Jong Chan | - |
dc.contributor.affiliatedAuthor | 김종찬 | - |
dc.contributor.affiliatedAuthor | 박지수 | - |
dc.contributor.affiliatedAuthor | 장원식 | - |
dc.contributor.affiliatedAuthor | 최영득 | - |
dc.contributor.affiliatedAuthor | 함원식 | - |
dc.citation.volume | 11 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 18784 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, Vol.11(1) : 18784, 2021-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.